{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Clear+Cell+Renal+Cell+Carcinoma&page=18", "query": { "condition": "Clear Cell Renal Cell Carcinoma", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 999, "total_pages": 100, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Clear+Cell+Renal+Cell+Carcinoma&page=19&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Clear+Cell+Renal+Cell+Carcinoma&page=17&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T09:15:30.441Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03200587", "title": "Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Cabozantinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2018-06-21", "completion_date": "2021-11-25", "has_results": false, "last_update_posted_date": "2024-07-03", "last_synced_at": "2026-10-14T09:15:30.441Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03200587" }, { "nct_id": "NCT01599754", "title": "Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Clear Cell Renal Carcinoma" ], "interventions": [ { "name": "Axitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SFJ Pharma Ltd. II", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 724, "start_date": "2012-04", "completion_date": "2018-05", "has_results": true, "last_update_posted_date": "2019-09-20", "last_synced_at": "2026-10-14T09:15:30.441Z", "location_count": 26, "location_summary": "La Jolla, California • Los Angeles, California • Palo Alto, California + 22 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Pleasant Hill", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01599754" }, { "nct_id": "NCT00606866", "title": "MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Renal Cell Carcinoma" ], "interventions": [ { "name": "placebo", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2004-07", "completion_date": "2008-06", "has_results": false, "last_update_posted_date": "2023-11-29", "last_synced_at": "2026-10-14T09:15:30.441Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00606866" }, { "nct_id": "NCT04187872", "title": "LITT and Pembrolizumab in Recurrent Brain Metastasis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Non-small Cell Lung Carcinoma (NSCLC)", "Renal Cell Carcinoma (RCC)", "Small-cell Lung Cancer", "Head and Neck Squamous Cell Cancer", "Classical Hodgkin Lymphoma", "Primary Mediastinal Large B-Cell Lymphoma", "Urothelial Carcinoma", "Microsatellite Instability-High Cancer", "Gastric Cancer", "Esophageal Cancer", "Cervical Cancer", "Hepatocellular Carcinoma", "Merkel Cell Carcinoma", "Brain Metastases, Adult" ], "interventions": [ { "name": "LITT + Pembrolizumab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 10, "start_date": "2020-01-10", "completion_date": "2023-12-01", "has_results": false, "last_update_posted_date": "2023-12-27", "last_synced_at": "2026-10-14T09:15:30.441Z", "location_count": 2, "location_summary": "Gainesville, Florida • Jacksonville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04187872" }, { "nct_id": "NCT03229083", "title": "Software Monitoring of Treatment Related Toxicities in Advanced Renal Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Advanced Renal Cell Carcinoma" ], "interventions": [ { "name": "Carevive software", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2019-07-24", "completion_date": "2025-02-14", "has_results": true, "last_update_posted_date": "2026-05-07", "last_synced_at": "2026-10-14T09:15:30.441Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03229083" }, { "nct_id": "NCT03228667", "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer", "Small Cell Lung Cancer", "Urothelial Carcinoma", "Head and Neck Squamous Cell Carcinoma", "Merkel Cell Carcinoma", "Melanoma", "Renal Cell Carcinoma", "Gastric Cancer", "Cervical Cancer", "Hepatocellular Carcinoma", "Microsatellite Instability", "Mismatch Repair Deficiency", "Colorectal Cancer" ], "interventions": [ { "name": "N-803 + Pembrolizumab", "type": "DRUG" }, { "name": "N-803 + Nivolumab", "type": "DRUG" }, { "name": "N-803 + Atezolizumab", "type": "DRUG" }, { "name": "N-803 + Avelumab", "type": "DRUG" }, { "name": "N-803 + Durvalumab", "type": "DRUG" }, { "name": "N-803 + Pembrolizumab + PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803 + Nivolumab + PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803 + Atezolizumab + PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803 + Avelumab + PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803 + Durvalumab + PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803 + Docetaxel + Pembrolizumab", "type": "DRUG" }, { "name": "N-803 + Docetaxel + Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2018-12-11", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-01-14", "last_synced_at": "2026-10-14T09:15:30.441Z", "location_count": 35, "location_summary": "Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 31 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "El Segundo", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03228667" }, { "nct_id": "NCT03538028", "title": "A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cervical Cancer", "Microsatellite Instability (MSI)-High Endometrial Cancer", "Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])", "Esophageal Cancer", "Hepatocellular Carcinoma", "Melanoma (Uveal Melanoma Excluded)", "Merkel Cell Carcinoma", "Mesothelioma", "MSI-high Colorectal Cancer", "Non-small Cell Lung Cancer (NSCLC)", "Ovarian Cancer", "Squamous Cell Carcinoma of the Head and Neck (SCCHN)", "Small Cell Lung Cancer (SCLC)", "Renal Cell Carcinoma (RCC)", "Triple-negative Breast Cancer", "Urothelial Carcinoma", "Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "INCAGN02385", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Incyte Biosciences International Sàrl", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2018-06-18", "completion_date": "2020-10-07", "has_results": false, "last_update_posted_date": "2020-10-30", "last_synced_at": "2026-10-14T09:15:30.441Z", "location_count": 4, "location_summary": "Los Angeles, California • Hackensack, New Jersey • Huntersville, North Carolina + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03538028" }, { "nct_id": "NCT00749320", "title": "Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Arterial Spin Labeling Magnetic Resonance Imaging", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2008-09", "completion_date": "2019-12", "has_results": false, "last_update_posted_date": "2020-02-26", "last_synced_at": "2026-10-14T09:15:30.441Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00749320" }, { "nct_id": "NCT05012371", "title": "Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Clear Cell Renal Cell Carcinoma", "Metastatic Clear Cell Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2022-02-16", "completion_date": "2027-10-25", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-14T09:15:30.441Z", "location_count": 3, "location_summary": "Tampa, Florida • Houston, Texas • Charlottesville, Virginia", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Houston", "state": "Texas" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05012371" }, { "nct_id": "NCT00923520", "title": "A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Carcinoma", "Breast Cancer", "Colon Cancer", "Lung Cancer", "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "DMS 612", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 60, "start_date": "2009-03-25", "completion_date": "2018-12-03", "has_results": false, "last_update_posted_date": "2018-12-05", "last_synced_at": "2026-10-14T09:15:30.441Z", "location_count": 3, "location_summary": "Bethesda, Maryland • Hershey, Pennsylvania • Pittsburgh, Pennsylvania", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Hershey", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00923520" } ] }